5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors.

Area of Science:

• Medicinal Chemistry
• Virology
• Drug Discovery

Background:

• HIV-1 integrase is a key target for antiviral chemotherapy.
• The lens-epithelium-derived-growth-factor-p75 (LEDGF/p75) binding site on integrase is crucial for viral replication.
• Inhibitors targeting this site disrupt integrase multimerization and viral replication.

Purpose of the Study:

• To synthesize and screen novel 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives.
• To evaluate their potential as HIV-1 replication inhibitors.
• To investigate structure-activity relationships and pharmacokinetic properties.

Main Methods:

• Synthesis of a series of tetrahydro-naphthyridine compounds.
• Screening for anti-HIV-1 activity in cell culture.
• Structure-activity relationship (SAR) studies.
• Pharmacokinetic studies in rats.

Main Results:

• Several derivatives demonstrated activity against HIV-1 infection.
• Compounds targeting the LEDGF/p75-binding site were identified.
• Lead compounds showed promising pharmacokinetic profiles in rats.

Conclusions:

• Tetrahydro-naphthyridine derivatives are effective inhibitors of HIV-1 replication.
• Targeting the LEDGF/p75-binding site offers a viable strategy for antiviral drug development.
• Further optimization and studies are warranted for clinical development.